After sparring with GSK’s ViiV Healthcare over the price of its HIV medication dolutegravir, Colombia appears to be taking matters into its own hands. Colombian a...

The Federal Trade Commission (FTC) recently came up short in its attempt to derail Amgen’s $27.8 billion acquisition of Horizon Therapeutics. But there is still cons...

Viatris just notched a win on its quest to reach $1 billion in eye care sales by 2028. The FDA on Wednesday approved Viatris and Ocuphire’s Ryzumvi, also known as...

A Massachusetts federal judge has sided with Eli Lilly in a patent spat, overturning a $176.5 million jury verdict from November of last year. The verdict had bee...

It’s been about 10 months since FDA inspectors rebuked a production plant in India that made popular platinum-based chemotherapies, kicking off a chain reaction of d...

While GSK’s Arexvy was first out the gate in this summer’s respiratory syncytial virus (RSV) vaccine race, Pfizer has kept the pressure up with its rival shot Abrysv...

Group aims to improve access to scientific programmes and grow ELRIG community. Cambridge, UK, 14 September 2023: The European Laboratory Research & Inno...

BMS-986278 was well tolerated and the treatment effect was found to be consistent with or without background therapy. Bristol Myers Squibb has reported results fr...

The overall response rate was 100% one month after treatment. PeproMene Bio has completed the first dose cohort of its Phase I clinical trial of PMB-CT01, a BAFFR...

The dose escalation trial will assess the biopharma’s SFK inhibitor candidate NXP900. Nuvectis Pharma will test its solid tumour treatment candidate for the first...